Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Effectiveness and Safety of Large Gel Particle Hyaluronic Acid With Lidocaine for Correction of Midface Volume Deficit or Contour Deficiency

Weiss, Robert A. MD; Moradi, Amir MD; Bank, David MD; Few, Julius MD; Joseph, John MD; Dover, Jeffrey MD; Lin, Xiaoming RN, MS; Nogueira, Alessandra MD; Mashburn, Jay PhD

Erratum

In the June 2016 issue of Dermatologic Surgery in the article by Weiss et al, “Effectiveness and Safety of Large Gel Particle Hyaluronic Acid With Lidocaine for Correction of Midface Volume Deficit or Contour Deficiency,” an oversight occurred in which the study investigators were not acknowledged in the publication. Therefore, the authors would like to acknowledge the contributions of all the principal investigators in the online version of the publication:

Study investigators included:

David Bank, MD (Mount Kisco, New York)

Fredric Brandt, MD (Miami, Florida)

Jeffrey Dover, MD (Chestnut Hill, Massachusetts)

Julius Few, MD (Chicago, Illinois)

Roy Geronemus, MD (New York, New York)

Richard Glogau, MD (San Francisco, California)

Mark Jewell, MD (Eugene, Oregon)

John Joseph, MD (Beverly Hills, California)

Amir Moradi, MD (Vista, California)

Mark Nestor, MD (Aventura, Florida)

Mark Rubin, MD (Beverly Hills, California)

Robert Weiss, MD (Hunt Valley, Maryland)

Independent photographic reviewer:

Michael Kane, MD (New York, New York)

Also, Xiaoming Lin’s disclosure statement failed to state that she is a Galderma employee.

Dermatologic Surgery. 42(10):1233, October 2016.

doi: 10.1097/DSS.0000000000000771
Original Article
Buy
Erratum

BACKGROUND Aging effects, such as facial flatness, increased tissue laxity, and soft tissue descent and deflation, contribute to midface deficiency.

OBJECTIVE To evaluate whether large gel particle hyaluronic acid with lidocaine (LGP-HAL) is more effective in the treatment of midface deficiencies than no treatment.

MATERIALS AND METHODS Subjects with mild to substantial loss of midface fullness were randomized 3:1 to LGP-HAL (Restylane Lyft; Galderma Laboratories, L.P., Fort Worth, TX) or no treatment. Treatment success was defined as at least 1-grade improvement in Medicis Midface Volume Scale (MMVS) on each side of the face at 8 weeks as assessed by a blinded evaluator. Secondary efficacy end points included MMVS score, global aesthetic improvement, and subject satisfaction.

RESULTS Significantly greater percent of subjects achieved treatment success in the LGP-HAL group compared to no treatment at all time points through Month 12 (p < .001). One year after initial treatment, 85% of subjects still had a global aesthetic improvement assessed by the treating investigator. Subject satisfaction demonstrated that LGP-HAL improved the aesthetic appearance of the midface. Most reported adverse events (80%) were mild in severity.

CONCLUSION The LGP-HAL treatment is well tolerated and provides significant improvement up to 12 months for the correction of midface deficiencies.

*Maryland Laser Skin and Vein Institute, Hunt Valley, Maryland;

Private Practice, Vista, California;

The Center for Dermatology, Cosmetic & Laser Surgery, Mount Kisco, New York;

§Private Practice, Chicago, Illinois;

Private Practice and Director of the Clinical Testing Center of Beverly Hills, Beverly Hills, California;

SkinCare Physicians, Chestnut Hill, Massachusetts;

#Galderma R&D, Uppsala, Sweden;

**Galderma Laboratories, L.P., Fort Worth, Texas

Address correspondence and reprint requests to: Robert Weiss, MD, Maryland Laser Skin and Vein Institute, 54 Scott Adam Road, Suite 301, Hunt Valley, MD 21030, or e-mail: rweiss@mdlsv.com

Supported by Medicis Corporation, a Division of Valeant Pharmaceuticals at the time of study execution.

Investigational sites where R. Weiss, A. Moradi, D. Bank, J. Few, J. Joseph, and J. Dover served as principal investigators received fees to conduct the trial. A. Nogueira and J. Mashburn are employees of Galderma Laboratories, L.P. The other author has indicated no significant interest with commercial supporters.

© 2016 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website